Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent
Authors:
Open Access
- 1 May 2010
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 391 (1-2) , 305-312
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid DissolutionJournal of Pharmaceutical Sciences, 2009
- Agglomerates Containing Pantoprazole Microparticles: Modulating the Drug ReleaseAAPS PharmSciTech, 2009
- Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategyInternational Journal of Pharmaceutics, 2009
- Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapyJournal of Pharmaceutical Sciences, 2008
- Pure Insulin Nanoparticle Agglomerates for Pulmonary DeliveryLangmuir, 2008
- Biodegradable Nanoparticle Flocculates for Dry Powder Aerosol FormulationLangmuir, 2007
- Overview of radiopaque drugs: 1895–1931American Journal of Health-System Pharmacy, 2006
- Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungsJournal of Controlled Release, 2004
- Pulmonary Delivery of Nanoparticles of Insoluble, Iodinated CT x-ray coNtrast Agents to Lung Draining Lymph Nodes in DogsJournal of Pharmaceutical Sciences, 1998
- Capillary electrophoresis determination of diatrizoic acid and its impurities in diatrizoate radiopaque solutionsMicrochimica Acta, 1997